Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume auto-injector ...

EWING, N.J., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced the successful regulatory outcome of the Makena ® subcutaneous auto injector collaboration with AMAG ...

Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE ® in 30 seconds using Halozyme's proprietary high-volume ...

TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (BIIB) (Nasdaq ...

Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE ® in 30 seconds using Halozyme's proprietary high-volume ...

AMAG Pharmaceuticals, Inc.AMAG announced positive top-line results from its pharmacokinetic (PK) study on its subcutaneous auto-injector, Makena. However, the company's shares crashed 7.5% due to some ...

WALTHAM, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) accepted the supplemental new drug ...

Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE ® in 30 seconds using Halozyme's proprietary high-volume ...

A new auto-injecting pill might soon become a replacement for subcutaneous injection treatments. The idea for this so-called robotic pill came out of a research project around eight years ago from ...